Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer

Chemotherapy

Volumn 45, Issue 3, 1999, Pages 197-204

  Tohda, Yuji ^a,f   Iwanaga, Takashi ^a   Takada, Minoru ^b   Yana, Takashi ^b   Kawahara, Masaaki ^c   Negoro, Shun Ichi ^d   Okishio, Kyoichi ^e   Kudoh, Shinzo ^e   Fukuoka, Masahiro ^a   Furuse, Kiyoyuki ^c  

^a KINKI UNIVERSITY   (Japan)

^b OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^c National Kinki Central Hospital for Chest Diseases   (Japan)

^d OSAKA CITY GENERAL HOSPITAL   (Japan)

^e Osaka Prefecture University   (Japan)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin, intrapleural; Etoposide, intrapleural; Malignant pleural effusions; Non small cell lung cancer; Survival rate

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; FEVER; HUMAN; INFECTION; INTRAPLEURAL DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA; PLEURA EFFUSION; PRIORITY JOURNAL; THORAX DRAINAGE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; SURVIVAL ANALYSIS;

EID: 0032904032     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007183     Document Type: Article

References (20)

1. Yamamoto M, Furuse K, Fukuoka M, Kawahara M, Arai R, Kodama N, Takada M, Nedoro S, Matsui K, Ryu S, Sakai N: Phase II studies of single agent and cisplatinum-based two drug combination in non-small cell lung cancer patients (in Japanese). Gan To Kagaku Ryoho 1988; 15:487-492.
2. Fukuoka M, Furuse K, Takada M, Negoro S, Tamai S, Matsui K, Sakai N, Ryu S, Yoshinaga T, Kawahara M, Tsuruta M, Kodama N, Arai R, Yamamoto M, Ohta K, Kusunoki Y, Shiota K: Phase II study of cis-dichlorodiammineplatinum (II) for non-small cell lung cancer (in Japanese). Gan To Kagaku Ryoho 1985; 12:471-478.
3. Kudoh S, Takifuji N, Ryu S, Sakai N, Matsui K, Negoro S, Tamai S, Takada M, Kusunnoki Y, Fukuoka M, Morino H: Response and pharmacokinetics of cisplatin instilled into the pleural cavity (in Japanese). Gyn To Kagaku Ryoho 1985;12: 2161-2165.
4. Uchida T, Okamoto K: Combination of etoposide with cisplatin or cyclophosphamide in the treatment of mouse Lewis lung carcinoma (in Japanese). Can To Kagaku Ryoho 1986;13:75-79.
5. Nishikawa K, Kusama K: Combination effects of etoposide with other antitumor drugs in vitro and in vivo (in Japanese). Gan To Kagaku Ryoho 1989;16:3739-3745.
6. Gotoh T, Nakamura T, Hiramori N, Fujii T, Fujita Y, Kida T, Arimoto T, Sakai M, Iwasaki Y, Tanaka Y, Torii Y, Ono N, Nakagawa M: Intrapleural administration of pirarubicin for the treatment of malignant pleural effusion (in Japanese). Gan To Kagaku Ryoho 1991;18:2121-2127.
7. Fukuoka M, Furuse K, Takada M, Negoro S, Tamai S, Matsui K, Sakai N, Ryu S, Yoshinaga T, Kawahara M, Tsuruta M, Kodama N, Arai R, Yamamoto M, Ohta K, Kasunoki Y, Shiota K: Phase II study of cis-dichlorodiammineplatinum (II) for non-small cell lung cancer. Jpn J Cancer Chemother 1985;12:471-478.
8. Jager RD, Longeval E, Klastersky J: High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: A phase II clinical trial of the EORTC lung cancer working party (Belgium). Cancer Treat Rep 1980;64:1314-1346.
9. Kimura K, Niitani H: A phase II study of nk171 (etoposide). Jpn J Chemother 1985;12:2011-2017.
10. John CR, Finkelstein DM, Ettinger DS, Creech RH, Mason A, Joss RA, Vogl S: A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986;4:14-22.
11. Goldhirsch A, Joss RA, Cavalli F, Sonntag RW, Brunner KW: Cis-dichloro-diammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer. Med Pediatr Oncol 1981;9:205-208.
12. Longeval E, Klastersky J: Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium). Cancer 1982;50:2751-2765.
13. Veronessi A, Zagonel V, Santarossa M, Tirelli U, Galligioni E, Trovo MG, Tumolo S, Grigoletto E: Cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma. Cancer Chemother Pharmacol 1983;11:35-37.
14. Scagliotti GV, Lodico D, Gozzelino F, Bardessono F, Albera C, Gatti E, Pescetti G: Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide. Oncology 1985;42:224-228.
15. Joss RA, Alberto P, Obrecht JP, Barrelet L, Holdener EE, Siegenthaler P, Goldhirsch A, Mermilllod B, Cavalli F: Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide. Cancer Treat Rep 1984;68:1079-1084.
16. Mitrou PS, Graubner M, Berdel WE, Mende S, Gropp C, Diehl V, Klippstein TH: Cis-platinum (DDP) and VP 16-213 (etoposide) combination chemotherapy for advanced non-small cell lung cancer. A phase II clinical trial. Eur J Cancer Clin Oncol 1984;20:347-351.
17. Dhingra HM, Valdivieso M, Booser DJ, Umsowosdi T, Carr DT, Chiuten DF, Mulphy WK, Spitzer G: Chemotherapy for advanced adenocarcinoma and squamous cell carcinoma of the lung with etoposide and cisplatin. Cancer Treat Rep 1984; 68:671-673.
18. Dhingra HM, Valdivieso M, Carr DT, Chiuten PF, Farha P, Murphy WK, Spitzer G, Umsawasdi T: Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1985;3:176-183.
19. Ruckdeschel JC, Finkel DM, Ettinger DS, Creech RH, Mason BA, Joss RF, Vogl S: A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986;4:14-22.
20. Buccheri G, Ferringo D, Curcio A, Vola F, Mattalia E: MACC (methotrexate, doxorubicin, cyclophosphamide and lomustine) versus cis-platinum and etoposide in the treatment of advanced non-small cell lung cancer. Chemioterapia 1986;5:53-57.